Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ASP015K in Renal Impairment
NCT02603497Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of peficitinib in rheumatoid arthritis (RA) (4 arms), sponsored by Astellas Pharma. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Infinity at 72 hours, Maximum Plasma Concentration at 72 hours and 6 more. Started Nov 2015; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02603497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603497.